Logo image of AVIR

ATEA PHARMACEUTICALS INC (AVIR) Stock Price, Quote, News and Overview

NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD

2.99  +0.04 (+1.36%)

After market: 2.99 0 (0%)

AVIR Quote, Performance and Key Statistics

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (5/1/2025, 4:30:01 PM)

After market: 2.99 0 (0%)

2.99

+0.04 (+1.36%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High4.14
52 Week Low2.6
Market Cap255.73M
Shares85.53M
Float75.46M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07/amc
IPO10-30 2020-10-30


AVIR short term performance overview.The bars show the price performance of AVIR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6 -8

AVIR long term performance overview.The bars show the price performance of AVIR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of AVIR is 2.99 USD. In the past month the price increased by 3.82%. In the past year, price decreased by -24.49%.

ATEA PHARMACEUTICALS INC / AVIR Daily stock chart

AVIR Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 61.08 752.80B
JNJ JOHNSON & JOHNSON 15.37 372.23B
NVO NOVO-NORDISK A/S-SPONS ADR 18.96 291.20B
NVS NOVARTIS AG-SPONSORED ADR 13.21 219.89B
AZN ASTRAZENECA PLC-SPONS ADR 18.95 218.61B
MRK MERCK & CO. INC. 10.69 209.51B
PFE PFIZER INC 7.45 135.72B
SNY SANOFI-ADR 14.02 132.44B
BMY BRISTOL-MYERS SQUIBB CO 6.76 100.94B
GSK GSK PLC-SPON ADR 7.05 78.52B
ZTS ZOETIS INC 26.29 69.43B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.67 47.30B

About AVIR

Company Profile

AVIR logo image Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Company Info

ATEA PHARMACEUTICALS INC

225 Franklin Street, Suite 2100

Boston MASSACHUSETTS 02110 US

CEO: Jean-Pierre Sommadossi

Employees: 75

Company Website: https://ateapharma.com/

Investor Relations: https://ir.ateapharma.com/

Phone: 18572048109

ATEA PHARMACEUTICALS INC / AVIR FAQ

What is the stock price of ATEA PHARMACEUTICALS INC today?

The current stock price of AVIR is 2.99 USD. The price increased by 1.36% in the last trading session.


What is the ticker symbol for ATEA PHARMACEUTICALS INC stock?

The exchange symbol of ATEA PHARMACEUTICALS INC is AVIR and it is listed on the Nasdaq exchange.


On which exchange is AVIR stock listed?

AVIR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ATEA PHARMACEUTICALS INC stock?

8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 104.68% is expected in the next year compared to the current price of 2.99. Check the ATEA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ATEA PHARMACEUTICALS INC worth?

ATEA PHARMACEUTICALS INC (AVIR) has a market capitalization of 255.73M USD. This makes AVIR a Micro Cap stock.


How many employees does ATEA PHARMACEUTICALS INC have?

ATEA PHARMACEUTICALS INC (AVIR) currently has 75 employees.


What are the support and resistance levels for ATEA PHARMACEUTICALS INC (AVIR) stock?

ATEA PHARMACEUTICALS INC (AVIR) has a resistance level at 3. Check the full technical report for a detailed analysis of AVIR support and resistance levels.


Should I buy ATEA PHARMACEUTICALS INC (AVIR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ATEA PHARMACEUTICALS INC (AVIR) stock pay dividends?

AVIR does not pay a dividend.


When does ATEA PHARMACEUTICALS INC (AVIR) report earnings?

ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of ATEA PHARMACEUTICALS INC (AVIR)?

ATEA PHARMACEUTICALS INC (AVIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).


What is the Short Interest ratio of ATEA PHARMACEUTICALS INC (AVIR) stock?

The outstanding short interest for ATEA PHARMACEUTICALS INC (AVIR) is 3.93% of its float. Check the ownership tab for more information on the AVIR short interest.


AVIR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AVIR. When comparing the yearly performance of all stocks, AVIR is a bad performer in the overall market: 71.56% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AVIR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AVIR. While AVIR has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AVIR Financial Highlights

Over the last trailing twelve months AVIR reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -21.95% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.24%
ROE -38.37%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%14.89%
Sales Q2Q%N/A
EPS 1Y (TTM)-21.95%
Revenue 1Y (TTM)N/A

AVIR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 50% to AVIR. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners69.11%
Ins Owners3.09%
Short Float %3.93%
Short Ratio8.98
Analysts
Analysts50
Price Target6.12 (104.68%)
EPS Next Y13.55%
Revenue Next YearN/A